Related references
Note: Only part of the references are listed.Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ
Shin-ichiro Fujii et al.
CANCER SCIENCE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Immunotherapy of sarcomas with modified T cells
Preethika Mahalingam et al.
CURRENT OPINION IN ONCOLOGY (2022)
Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].
Dejka M. Araujo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Soft Tissue Sarcoma, Version 2.2022
Margaret von Mehren et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
THE EPI-RTM TECHNOLOGY PRODUCES A POLYCLONAL TIL PRODUCT (LYL845) WITH A GREATER EXPANSION SUCCESS RATE ACROSS HOT AND COLD TUMORS, IMPROVED PRODUCT PHENOTYPE, AND MAINTENANCE OF TCR DIVERSITY
Yogin Patel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
IMPROVED ANTI-TUMOR ACTIVITY OF NEXT-GENERATION TCR-ENGINEERED T CELLS THROUGH CD8 CO-EXPRESSION
Gagan Bajwa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
SAFETY AND ANTI-TUMOR ACTIVITY OF TCR-ENGINEERED AUTOLOGOUS, PRAME-DIRECTED T CELLS ACROSS MULTIPLE ADVANCED SOLID CANCERS AT LOW DOSES - CLINICAL UPDATE ON THE ACTENGINE® IMA203 TRIAL
Martin Wermke et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II study of alpha-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
Takahide Toyoda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Sri Krishna et al.
SCIENCE (2020)
FINAL ANALYSIS OF THE PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC T-CELL RECEPTOR (TCR) T-CELL THERAPY (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA (SS)
Sandra D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis
Mahmut Nedim Aytekin et al.
JOURNAL OF ORTHOPAEDIC SURGERY (2020)
Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma
Takuya Kakimoto et al.
ONCOLOGY LETTERS (2019)
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
Matthew J. McBride et al.
CANCER CELL (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
Brittany C. Michel et al.
NATURE CELL BIOLOGY (2018)
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Gerard L. Brien et al.
ELIFE (2018)
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
Kunio Iura et al.
HUMAN PATHOLOGY (2017)
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
Jason Roszik et al.
CLINICAL SARCOMA RESEARCH (2017)
Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1 c259t. in HLA-A2+ patients with synovial sarcoma (NCT01343043).
Crystal Mackall et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
David Remillard et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition
Natalie H. Theodoulou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity
Myrella Vlenterie et al.
EUROPEAN JOURNAL OF CANCER (2016)
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
Laetitia J. Martin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Age as an independent prognostic factor for survival of localised synovial sarcoma patients
Myrella Vlenterie et al.
BRITISH JOURNAL OF CANCER (2015)
The MAGE protein family and cancer
Jenny L. Weon et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains
Duncan A. Hay et al.
MEDCHEMCOMM (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4
Lynnette Marcar et al.
PLOS ONE (2015)
Adoptive T Cell Immunotherapy for Cancer
Karlo Perica et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2015)
High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine
Takuro Saito et al.
VACCINE (2014)
Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer
Gavin M. Bendle et al.
JOURNAL OF IMMUNOLOGY (2013)
Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
Shin-ichiro Fujii et al.
ONCOIMMUNOLOGY (2013)
Incidence of soft tissue sarcoma and beyond
Giuseppe Mastrangelo et al.
CANCER (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors
A. H. Krieg et al.
ANNALS OF ONCOLOGY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mage-A Cancer/Testis Antigens Inhibit p53 Function by Blocking Its Interaction with Chromatin
Lynnette Marcar et al.
CANCER RESEARCH (2010)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
Stefan Sleijfer et al.
EUROPEAN JOURNAL OF CANCER (2010)
Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia
Frances Wadelin et al.
MOLECULAR CANCER (2010)
Comparing Children and Adults With Synovial Sarcoma in the Surveillance, Epidemiology, and End Results Program, 1983 to 2005 An Analysis of 1268 Patients
Iyad Sultan et al.
CANCER (2009)
The diagnostic value of SYT-SSX detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) for synovial sarcoma:: A review and prospective study of 255 cases
Baocun Sun et al.
CANCER SCIENCE (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
Khoi Q. Tran et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma
Fritz C. Eilber et al.
ANNALS OF SURGERY (2007)
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: an analysis of 26,758 cases
Jorge R. Toro et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: A potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma
Tsuyoshi Saito et al.
CANCER RESEARCH (2006)
Detection and functional analysis of CD8+ T cells specific for PRAME:: a target for T-cell therapy
Marieke Griffioen et al.
CLINICAL CANCER RESEARCH (2006)
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface
L Wooldridge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
A Ferrari et al.
CANCER (2004)
Primary adult soft tissue sarcoma: Time-dependent influence of prognostic variables
A Stojadinovic et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity
CM Bollard et al.
BLOOD (2002)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations
K Cao et al.
HUMAN IMMUNOLOGY (2001)
Monitoring CD8 T cell responses to NY-ESO-1:: Correlation of humoral and cellular immune responses
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
